Lifeboat Foundation

Modern theories of semantics posit that the meaning of words can be decomposed into a unique combination of semantic features (e.g., “dog” would include “barks”). Here, we demonstrate using functional MRI (fMRI) that the brain combines bits of information into meaningful object representations. Participants receive clues of individual objects in form of three isolated semantic features, given as verbal descriptions. We use machine-learning-based neural decoding to learn a mapping between individual semantic features and BOLD activation patterns. The recorded brain patterns are best decoded using a combination of not only the three semantic features that were in fact presented as clues, but a far richer set of semantic features typically linked to the target object. We conclude that our experimental protocol allowed us to demonstrate that fragmented information is combined into a complete semantic representation of an object and to identify brain regions associated with object meaning.

When they looked into how various physiological factors changed in the mice that had experienced chronic stress, the researchers closed in on a hormone called epinephrine.

New research in mice explains the mechanism through which chronic stress contributes to cancer cell growth and suggests a potential therapeutic strategy.

The researchers have examined blood samples from 702 pregnant Danish women who were registered in the database “Aarhus Children’s Biobank”. Such thorough studies of the concentration of perfluorinated substances and their biological effect in pregnant woman have not been done previously, but the study is nevertheless in line with previous research in the area. The substances have furthermore been associated with a range of issues including breast cancer, fertility problems, ADHD, the risk of asthma, a weakened immune system and the reduced effect of vaccines.

For the first time, researchers have shown that a combination of perfluorinated substances in the mother significantly inhibits child growth. These are the substances which Denmark’s minister for environment and food is currently working to ban.

On Monday, April 8th, we will be hosting our second research webinar, during which we will be discussing the microbiome and its role in aging and disease.

Our second research webinar

Our work is largely supported by the generosity of our monthly patrons, the Lifespan Heroes, so to thank them we have launched a new series of exclusive webinars where Heroes can join the researchers live, listen to discussion panels, and take part in Q&A sessions.

Click on photo to start video.

This pillow claims to reduce acid reflux symptoms — I decided to try it.

I wonder how diet mixed with CBD oil treatment can work on neurodegenerative diseases? A man has told of how he “got his mum back” after a diagnosis of Alzheimer’s disease, in part, by getting her to follow a diet high in berries and leafy green vegetables.

One man has ‘got his mum back’ from the ravages of Alzheimer’s, partly…

#ClinicalTrial The most common syndrome in patients with severe dementia is agitated behavior, which is often characterized by a combination of violent behavior (physical or verbal), restlessness, and inappropriate loudness. The treatment options for this syndrome are limited and lead to severe side effects. In vivo experiments on animals and clinical studies on adults show that cannabinoids could have a beneficial effect on behavioral disorders in general, and in dementia-related disorders in particular.

Full Text View.

Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes. While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD) and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE). Current basic science and clinical investigations support the safety and efficacy of such interventions in treatment of these currently intractable conditions, that in some cases share pathological processes, and the plausibility of interventions that harness endocannabinoid mechanisms, whether mediated via direct activity on CB₁ and CB₂ (tetrahydrocannabinol, THC, caryophyllene), peroxisome proliferator-activated receptor-gamma (PPARγ; THCA), 5-HT_1A (CBD, CBDA) or even nutritional approaches utilizing prebiotics and probiotics. The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment.

Keywords: cannabis, pain, brain tumor, epilepsy, Alzheimer disease, Parkinson disease, traumatic brain injury, microbiome.

Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840; Russo, 2017b), who described remarkable successes in treating epilepsy, rheumatic pains, and even universally fatal tetanus with the “new” drug. Cannabis, or “Indian hemp,” was rapidly adopted by European physicians noting benefits on migraine by Clendinning in England (Clendinning, 1843; Russo, 2001) and neuropathic pain, including trigeminal neuralgia by Donovan in Ireland (Donovan, 1845; Russo, 2017b). These developments did not escape notice of the giants of neurology on both sides of the Atlantic, who similarly adopted its use in these indications: Silas Weir Mitchell, Seguin, Gowers and Osler (Mitchell, 1874; Seguin, 1877; Gowers, 1888; Osler and McCrae, 1915).